It is with great enthusiasm that we welcome you to the 3rd Kuwait Hematology Conference (KHC). Building on the success and momentum of previous editions, this year’s conference will bring together a distinguished panel of hematologists, researchers, and clinicians to share the latest advancements, clinical practices, and research findings in both benign and malignant hematology.
The conference is designed to present recent updates in diagnostic and therapeutic hematology, highlight case-based approaches for both common and rare hematologic disorders, foster interdisciplinary collaboration and knowledge exchange across specialties, and provide hands-on workshops that support clinical decision-making.
Our target audience includes hematologists (adult and pediatric), oncologists, internists, hematopathologists, laboratory specialists, clinical pharmacists, trainees and fellows in hematology, oncology, and internal medicine, as well as allied health professionals involved in hematologic care.
Each session will feature 2–3 expert presentations followed by a moderated Q&A to encourage interactive learning and clarify key takeaways. Satellite symposia and coffee breaks are thoughtfully arranged to enhance networking opportunities. Additionally, workshops are case-based and interactive, led by respected clinicians and educators, ensuring a practical and engaging educational experience for all participants.
See you at the conference!
Yours Sincerely, Conference Chairperson
Dr. Huda Alsahhaf
Consultant of Internal Medicine and Clinical Hematology at Jaber Al-Ahmad Hospital
Target Audience
Target Audience
This conference is designed for all healthcare professionals engaged in the prevention, diagnosis, and management of hematologic disorders, including (but not limited to):
Adult and pediatric hematologists
Medical oncologists and internists
Hematopathologists and laboratory medicine specialists
Clinical pharmacists involved in hematology care
Trainees and fellows in hematology, oncology, and internal medicine
Allied health professionals supporting hematologic services
Conference Agenda
Conference Agenda
Friday, 14 November 2025
Theme one : Plasma cell dyscrasias Dr. Mohammad Soliman & Dr. Ahmad Alhuraiji
09:00 - 09:20 AM
Multiple Myeloma Clues — A Practical Framework for Early Detection and Timely Referral
Dr. Ibrahim Al Nabhani
09:20 - 09:40 AM
Unmasking Amyloidosis: A Case-Based Journey Through Light Chain Disease
Dr. Abdullah Alamer
09:40 - 09:50 AM
Q&A
Theme Two: Hemostasis and bleeding Dr. Huda Alsahhaf & Dr. Anwar Al Mesabahi
Challenges in vWD: Diagnosis, Management, & Role of Prophylaxis including non-factor replacements
Dr. Eman Al Shamsi 🇦🇪
10:30 - 10:50 AM
iTTP: the role of new therapies in omitting plasma exchange and refractory disease
Prof. Flora Payvandi
10:50 - 11:00 AM
Q&A
11:00 - 11:15 AM
Coffee Break
11:15 - 12:00 PM
Friday Prayer Break
12:00 - 12:20 PM
Satellite Symposium:Pegcetacoplan in PNH patients with Aplastic Anemia
Dr. Shaykhah Alotaibi
12:20 - 12:25 PM
Q&A
Theme Three: Leukemia pediatrics to adults Dr. Ali Mullah-Ali & Dr. Fatma Khadada
12:25 - 12:45 pm
Precision Medicine in Childhood Cancer: Introducing Novel Therapies for Pediatric Acute Lymphoblastic Leukemia
Dr. Hamze Kaddoura
12:45 - 01:05 PM
From diagnosis to deep remission: A modern journey through pediatric leukemia
Dr. Maha Bourusly
01:05 - 01:40 PM
Adult leukemia
Dr. Naval Daver 🇺🇸
01:40 - 01:50 PM
Q&A
01:50 - 02:30 PM
Lunch Break
Theme Four: Obstetric Hematology: Dr. Salha Alfoudari
02:30 - 02:50 PM
Transfusion requirements during pregnancy
Dr. Sheikha Al-Zanki
02:50 - 03:10 PM
Thromboprophylaxis in pregnancy – Special Situations
Dr. Mari Thomas
03:10 - 03:20 PM
Q&A
Theme Five: Lymphoproliferative disorders Dr. Abdulaziz Hamada & Dr. Hashem Al Mousawi
03:20 - 03:40 PM
The New Equation in LCH
Dr. Nisreen Khalifa
03:40 - 03:50 PM
Coffee break
03:50 - 04:10 PM
Cutaneous lymphoma
Prof. Pierluigi Zinzani
04:10 - 04:30 PM
Relapsed refractory DLBCL in unfit pts
Dr. Kirit M Ardeshna
04:30 - 04:40 PM
Q&A
End of Day One
Friday, 14 November 2025
Theme: Clinical highlights : Dr. Muna Alrasheed & Dr. Lulwa Al Toura
09.00 - 10.00 AM
Immune thrombocytopenia : going through latest guidelines and sharing experience in challenging cases
Dr. Muna Alrasheed
10.00 - 11.00 AM
Challenging cases in CVT and Splanchnic vein thrombosis
Dr. Bader Al-Rawahi
11.00 - 12.00 PM
Prayer Break
Theme: Laboratory highlights: Dr. Mariam Jumaa & Dr. Huda Zartaj
12.00 - 01.00 PM
Behind the transfusion medicine curtain: Challenging Immunohematology cases
Dr.Marwa AlSayed
01.00 - 02.00 PM
Decoding MDS: A diagnostic journey through morphology and molecular testing: case based perspective
Dr. Dina Elkady
Saturday, 15 November 2025
Theme six: Myeloproliferative disorders Dr. Ahmad Alabdulkarim & Dr. Ahmad Alsaffar
09:00 – 09:20 AM
Optimizing Allografting for Myelofibrosis in 2025
Dr. Donal McLornan
09:20 – 09:40 AM
Triple negative MPNs: Diagnostic challenges and clinical management
Dr. Ahmad Alabdulkarim
09:40 – 10:00 AM
Satellite Symposium: Advances in CML Management Strategies and Real-World Experiences with SCEMBLIX
Dr. Muna Al Rasheed
10:00 - 10:10 AM
Q&A
Theme seven: Bone Marrow Transplantation Dr. Salem Al Shammeri & Dr. Samar Ousia
10:10 – 10:30 AM
Outcomes of haploidentical transplantation in hemoglobinapathies
Prof. Josu de la Fuente
10:30 – 10:50 AM
Haplo or Edit? navigating the future of TDT and sickle cell disease through gene therapy and alternative transplantation
Prof. Josu de la Fuente
10:50 - 11:00 AM
Q&A
11.00 - 11.20 AM
CAR-T therapy outcomes and challenges
Dr. Manel Juan
11:20 – 11:40 AM
Updates in aplastic anemia management
Dr. Panagiotis Kottaridis
11.40 - 11.50 AM
Q&A
11:50 - 12:15 PM
Prayer & Coffee Break
Theme eight: Thrombosis Dr. Ali Aljeriwi & Dr. Lulwa Al Toura
12:15 - 12:35 PM
ApiCAT trial and cancer associated thrombosis
Dr. Bader Al-Rawahi
12:35 - 12:55 PM
Catheter related thrombosis Overview, management and updates
Dr. Lulwah Altourah
12:55 - 01:05 PM
Q&A
Theme nine: Hemoglobinopathies Dr. Noura Aljiwaisri & Dr. Abdullah Al Otaibi
01:05 - 01:25 PM
Approved & investigational therapies in hemoglobinopathies
Prof. Farjah Alqahtani
01:25 - 01:45 PM
Where are we now in gene therapy?
Dr. Shaykhah Alotaibi
01:45 - 02:00 PM
Q&A
02:00 – 02:30 PM
Opening ceremony
02:30 - 03:15 PM
Lunch break & Exhibition
Theme ten: Updates on rare diseases Dr. Muna Alrasheed & Dr. Taghreed Al Essa
03:15 – 03:45 PM
PNH
Dr. Richard Kelly
03:45 - 04:05 PM
Acute intermittent porphyria (AIP)
Dr. Mohamed Abuhaleeqa 🇦🇪
04:05 – 04:15 PM
Q&A
04:15 – 04:30 PM
Poster presentations & prizes
04:30 – 04:40 PM
Ending Remarks
Saturday, 15 November 2025
Theme: Hematology made easy Dr.Mariam Alfaili & Dr. Yasmine Al Qattan
09.00 - 10.00 AM
Approach to anemia: case based
Dr. Nouf Alkandari
10.00 - 11.00 AM
Approach to thrombocytopenia: case based
Dr. Noura Aljuwaisri
11.00 - 12.00 PM
A glimpse at white cell disorders: case based discussion
Dr. Hanan Al Wazzan
12.00 - 01.00 PM
Transitioning Anticoagulants in Atrial Fibrillation
Dr. Ahmad Al Qalaf
01:00 - 02:00 PM
Case based approach to the management of hematological emergencies
Dr. Yasmine Al Qattan
Theme: Pediatric Hematology: Dr. Hadeel Saleh
03:00 - 04:00 PM
How to approach bleeding disorder of Unkown cause BDUC
Dr. Hadeel Saleh
Theme: Malignant hematology Dr. Ahmad Alhuraiji / Dr. Ahmad AlAbdulkareem / Dr. Bilal Alnouri
04.00 - 05.00 PM
The changing landscape of low risk MDS treatment
Dr. Ahmad Alabdulkarim
05.00 - 06.00 PM
Diagnostic approach & Case based discussion
Dr. Wala Awny
Dr. Anitha Kunhikrishnan
Speakers
Our Speakers
Dr. Ibrahim Al Nabhani
Dr. Al Nabhani is a Consultant Hematologist and Assistant Professor at the College of Medicine and Health Sciences, Sultan Qaboos University, and the National Omani Center for Blood Diseases and Bone Marrow Transplant. Dual-board certified in internal medicine and hematology in Canada, he completed advanced training in lymphoma, myeloma, autologous stem cell transplantation, and CAR-T cell therapy at the Princess Margaret Cancer Center, Toronto. He is actively involved in clinical care, research, and medical education, driving advancements in hematology therapeutics in Oman.
Dr. Abdullah Alamer
Dr. Alamer is a Hematology Consultant at the lymphoma and myeloma section at the department of Hematology, Cancer center of excellence at King Faisal specialist hospital and research center. Dr. Alamer did his medical training in Canada and he is American and Canadian board certified, he did his Lymphoma and Myeloma fellowship at the university of Toronto. Dr. Alamer is a fellow of the Royal College of physicians and surgeons of Canada. His Main focus and interest is in Lymphoma, Myeloma and plasma cell disorders
Prof. Flora Payvandi
FLORA PEYVANDI is professor of Internal Medicine at the University of Milan, Italy and director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center of the Milan Policlinic Hospital, Italy. Her research started with molecular and biochemical characterization of coagulation disorders aiming at the development of novel treatment for the affected patients. Her research continued with the understanding of the microvascular dysfunctions in order to implement/develop and standardize innovative diagnostic and therapeutic strategies. Since many years, Dr. Peyvandi has been participating in clinical, educational and research activities of different European and International scientific societies and patients’ organizations. She served as President of the International Society of Thrombosis and Haemostasis and President of the Executive Committee of the European Association for Haemophilia and Allied Disorders. She is currently advisor on the European Agency of Medicine and member of the Technical Health Committee of the Italian Ministry of Health. Her clinical, teaching and research experience combined with her life in different countries, led her to familiarize with patient management, scientific projects and educational systems of different parts of the world.
Dr. Eman Al Shamsi 🇦🇪
Dr. Eman Taryam AlShamsi is currently a Consultant and the Head of the Pediatric Hematology Oncology Department at Al Jalila Children's Specialty Hospital. Clinical Assistant Professor of Oncology at Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU).
She graduated in 2002 from the Faculty of Medicine & Health Sciences at the United Arab Emirates University.
After graduation, Dr. AlShamsi trained and practiced at Tawam Hospital, UAE, from 2005. She served as staff from January 2017 until June 2021 when she joined Al Qassimi Women and Children Hospital (AQWCH) as a Consultant in Hematology Oncology and Head of Department. In August 2023, she moved to Al Jalila Children's Specialty Hospital, taking on her current role.
Dr. AlShamsi holds the Arab Board Diploma of Medical Specialization in Pediatrics and a diploma from the Royal College of Paediatrics and Child Health (RCPCH). She also obtained a Diploma in Clinical Research affiliated with the Vienna School of Clinical Research. She completed her clinical fellowship in Pediatric Hematology Oncology and Bone Marrow Transplant at SickKids Hospital in Toronto, Canada. This fellowship included training in Pediatric Clinical Hematology Oncology, Bone Marrow Transplant, and Thrombosis. Additionally, she attended an administrative fellowship program at MD Anderson Cancer Center in Texas, USA.
Throughout her career, Dr. AlShamsi has been involved in several ongoing collaborative research projects at Tawam and AQWCH hospitals, MBRU, UAEU, and Zayed University, with publications on PubMed. She has authored and reviewed chapters on bleeding disorders and pediatric cancers for upcoming medical textbooks.
Dr. AlShamsi hosted the SIOP Asia Conference in Abu Dhabi in April 2019. She actively participates in numerous national and international committees and activities, including the Scientific Sub-Committee of the International Medical Awards 2023-2024 (Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Science), the Transfusion Committee at AQWCH/AQH, and the NIHS Pediatric Hematology Oncology Accreditation (Head of the Sub-Committee). She is also involved in national bone marrow transplants, cancer screening, and prevention initiatives, as well as the SIOP and Women Leaders in Pediatric Oncology (WLPO). Her patient support and awareness activities include work with CCI and Friends of Cancer Patients UAE (FOCP). In recognition of her contributions, Dr. AlShamsi received the EOS Cancer Awareness Advocate of the Year 2024 Award from the Emirates Oncology Society.
Dr. Shaykhah Alotaibi
Hematologist in KFSH riyadh, intersted in hemoglopinopathies and bone marrow failure sydrome.
Dr. Hamze Kaddoura
1992: Graduated from Medical school at University of Ancona in Italy.
2000: Completed residency in Pediatrics and training in pediatric hematology/oncology at Children University Hospital in Ancona, Italy.
2000 to 2013: worked in Saudi Arabia at King Faisal Specialist Hospital and King Fahad Specialist Hospital as Consultant Ped. hematology/oncology.
2013-present: working as Consultant pediatric hematologist at NBK Children's Cancer Center in Kuwait.
Dr. Maha Bourusly
Dr Maha Jassim Bourusly is a pediatric consultant at the department of hematology and oncology at the NBK Children's Hospital in Kuwait. Dr Maha received her Bachelor of Medicine and Surgery from Kuwait University, 1990, She received her Diploma in child health, Dublin (DCH) 1994. And Kuwait Board in Pediatrics (PGTP) 2002. And MRCPCH (UK) 2003. Dr Maha Joined the department of hematology and oncology at the NBK Children's Hospital in Kuwait in 2003. Over her 32 years of practice, Dr. Maha has developed experience in general Pediatrics and pediatric hematology and leukemia, and shared these experiences through scientific literature and mentoring young pediatricians . She headed the Thalassemia league up until recently, and currently VP Pediatric league, Kuwait Medical Association. She is also board member and Co- founder of I want to learn society, an initiative to teach children at hospital with chronic debilitating illnesses.
Dr. Naval Daver 🇺🇸
Dr. Naval Daver is a professor and director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease, and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials in these diseases, including multiple registration and label enabling trials. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr Daver has published more than 500 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals. He also serves as Chair on numerous national and international meetings and educational platforms.
Dr. Sheikha Al-Zanki
Dr. Sheikha Al-Zanki graduated from the Faculty of Medicine, Kuwait University, in 2009 and completed her postgraduate training in Internal Medicine at the Kuwait Institute for Medical Specializations (KIMS) in 2016. She pursued a two-year subspecialty fellowship in Obstetric Medicine in 2021 and has been a Member of the Royal College of Physicians (UK) since 2017. Currently, she serves as a Senior Specialist in Obstetric Medicine at Farwaniya Hospital, providing inpatient and outpatient care for women with complex medical conditions in pregnancy. She is also engaged in research, teaching, and conferences, with publications in maternal health.
Dr. Mari Thomas
Dr Mari Thomas is a Consultant Haematologist at UCLH specialising in Haemostasis and Thrombosis. She leads the Obstetric Haematology service at UCLH, part of the regional Maternal Medicine network.
Dr. Nisreen Khalifa
Dr Nisreen M. Khalifa is a Consultant Pediatric Oncologist in the Solid Tumor Unit at the NBK Children's Hospital in Kuwait. Dr. Khalifa received her MD degree in 1992 from Assiut University in Egypt and completed her training in General Pediatrics in Assiut University Hospitals. She received her MSc degree in Pediatrics from Assiut University in 1997. Dr. Khalifa started her career in Oncology at the South Egypt Cancer Institute in Assiut University in 1998. She trained at National Cancer Institute. Cairo University before receiving her PhD in Pediatric Oncology in 2006 and becoming a faculty member at the South Egypt Cancer Institute. Dr. Khalifa joined the Pediatric Unit in the Medical Oncology Department at the Kuwait Cancer Control Centre in 2007. She later joined the Pediatric Hematology/Oncology Department at the NBK Children's Hospital as a consultant. Over her 20 years of practice, Dr. Khalifa has developed experience in solid tumors in children including sarcomas, brain tumors and malignant lymphomas.
Prof. Pierluigi Zinzani
Born in Arenzano (GE) 9th March, 1959 • High School Qualification, in 1978 • Graduated in Medicine and Surgery, with honours at the University of Bologna, in 1984 • Obtained the Speciality in Hematology, with honours at the University of Bologna, in 1987 • Awarded a “Post-Doctoral Fellowship in Medical Oncology” released by the “Roger Williams Cancer Center” of Providence (USA) in 1989. • Chief of the clinical and translational program of the Lymphoma Unit at the Institute of Hematology and Medical Oncology “L. & A. Seràgnoli” from 1990. • Member of the Italian Society of Hematology from 1986 • Member of the Italian Society of Experimental Hematology from 1987 • Member of the American Society of Hematology from 1989 • Member of the American Society of Clinical Oncology from 1989 • Associated Professor at the Institute of Hematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna from November 2002 • Since 12 November 2018, Full Professor of Hematology at the University of Bologna • Since 1 November 2024, Head of Institute of Hematology “Seràgnoli” University of Bologna • Served as the principal investigator of more than 280 clinical trials (including phase 1 and 2 studies followed by expansion cohorts) in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia including national and international multicenter studies • President of Italian Foundation on Lymphoma (FIL) from November 2013 to November 2015 and now he is a member of the Board of Directors • Actual President of the Italian Society of Hematology from January 1, 2025 • Associate Editor of Annals of Oncology from January 2014 to December 2017 and he acts as a reviewer for journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Haematologica, Leukemia & Lymphoma, Leukemia, Clinical Lymphoma Myeloma, Blood Advance, Lancet Hematology • He has presented his research at more than 525 national and international meetings • He has authored over 840 peer-reviewed papers in journals such as New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Annals of Oncology, Oncologist, Journal Hematology & Oncology, Haematologica, Blood Advances • His current research interest includes clinical trial methodology, prognostic factors in NHL, Hodgkin’s disease, chronic lymphocytic leukemia, new drugs development, and hairy cell leukemia
Dr. Kirit M Ardeshna
Dr Kirit Ardeshna is a consultant haematologist specialising in the management of patients with Hodgkin's and non Hodgkin's lymphoma. Over the past 20+ years he has been very active in clinical trials including being Global or UK Chief Investigator in several clinical trials which have brought novel treatments to the clinic. He has been the Clinical Director of the Cancer Division at University College London Hospitals since 2013 helping it to become one of the most high profile cancer centres in Europe
Dr. Donal McLornan
Dr Donal McLornan works as a consultant in the MPN, allogeneic transplant and CAR-T team at University College London Hospital, which has the largest transplant and academic CAR T program in the UK. He is the current chair of the Chronic Malignancy Working Party of the EBMT and is co-chair of the scientific council. Additionally, he is the vice chair of the Global Outreach Committee of EHA and chairs the UK wide National Cancer Research Institute MPN group. He has a particular interest in MPN, MPN/MDS overlap and allogeneic stem cell transplantation. His research and clinical trial portfolio focuses on Myelofibrosis and blast phase disease and he has published widely on these topics with >200 publications.
Dr. Ahmad Alabdulkarim
Specialist Haematologist at Jaber Alahmad Hospital Royal College of Surgeons Ireland - MD Kuwait Board of Haematology Clinical Fellowship in Myeloproliferative Neoplasms and Myelodysplastic syndromes - University College London Hospital Clinical Tutor in Kuwait Institute of Medical Specialisations
Dr. Muna Al Rasheed
Prof. Josu de la Fuente
Josu de la Fuente is a Consultant Haematologist at Imperial College Healthcare NHS Trust and Professor of Practice (Cellular and Gene Therapies), Imperial College London. He is the Director of the Paediatric Blood & Marrow Transplant Programme, specialising in transplantation for haemoglobinopathies and bone marrow failure, and being innovative in the use of alternative donors. He is also the lead for gene therapy and BMT for haemoglobinopathies across all ages. He is the Secretary of the Haemoglobinopathy Working Party of EBMT, board member of the Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party of EBMT and principal investigator and member of the steering committee of several gene therapy trials in sickle cell disease, thalassaemia and Diamond Blackfan anaemia syndrome.
Dr. Manel Juan
Spanish specialist in Immunology (since 1994) and Head of the Immunology Department at Hospital Clínic de Barcelona (HCB) since 2020. Over the past six years, his work has centered on antitumor cellular immunotherapy, with a particular focus on CAR-T therapies, where he has played a key role in the development of innovative, hospital-based therapeutic options. As a researcher, Dr. Juan leads the group *Immunogenetics of the Immune and Autoinflammatory Response* (since 2019), where his studies span T lymphocyte function, from the molecular mechanisms of adhesion and the role of chemokines, to the influence of HLA polymorphisms in infection, allergy, and histocompatibility. His research has progressively converged on the antitumor immune response, especially through CAR-T cells and transgenic T-cell receptors. He is principal investigator in more than 24 projects, with more than 250 scientific articles, two dozen reviews and book chapters, and 8 patents. His publications amount to a cumulative impact factor exceeding 710, with an H-index of 52.
Dr. Panagiotis Kottaridis
Dr Panos Kottaridis is a Consultant Haematologist in Leukaemia/MDS, Bone Marrow Transplantation and Cellular therapies at University College London Hospitals NHS Foundation Trust. His main academic and clinical interests focus on prognostication of Acute Myeloid Leukaemia, Bone Marrow Transplantation, Late Effects of chemotherapy/infertility in chemo and stem cell recipients and immunotherapies.
He is a member of the National Cancer Research Network (Former MRC) working party for AML since 2004 and has published more than 90 papers in peer reviewed journals. His work has attracted more than 9000 citations. He has also contributed with 2 chapters in Haematology textbooks. He is an enthusiastic teacher and lecturer
Dr. Bader Al-Rawahi
Senior consultant hematologist at the national hematology and bone marrow transplant center, University Medical city. Has bachelor's degree and MD from College of Medicine, Sultan Qaboos University. Finish Internal Medicine residency at McGill University, Canada. Finished Hematology residency at McGill University, Canada. Finish clinical and research fellowship in thrombosis from University of Ottawa, Canada. Has master's degree in epidemiology and public health from University of Ottawa, Canada. American Board certified in Internal Medicine. American Board certified in Hematology. Canadian board certified in Internal Medicine. Canadian board certified in Hematology. Main field of interest is thrombosis and hemostasis.
Dr. Lulwah Altourah
Graduate of KU Medical School KBH Graduate 2018 Thrombosis and Hemostasis Fellowship McMaster 2022-2024
Prof. Farjah Alqahtani
Farjah H. Alqahtani, MD, MPH, Professor in the Faculty of Medicine, Senior Scientist at King Saud University, Riyadh, Kingdom of Saudi Arabia. Supervisor of the Chair of Epidemiology and Public Health Research, Director of the Lymphoma fellowship program at King Saud University, the Division of Hematology, Department of Medicine, King Saud University, Master's degrees in Public Health from Johns Hopkins Bloomberg School of Public Health, and obtained a certificate from Harvard Medical School's global clinical scholars Research Training Program Prof. Alqahtani's Clinical research focuses on hematological disease, venous thromboembolic disease, Myleoproliferative disaese and malignant lymphoma, specifically in hemoglobinopathies, including Sickle cell disease/Thalassemia, on understanding disease progression, long-term outcomes, preventing organ damage, and developing disease-modifying drugs. Prof Alqahtani's is a strong advocate to improving healthcare provision to those afflicted by such conditions. Involved in many projects, Prof. Alqahtani is currently participating in numerous industry-sponsored trials, has published many important articles on sickle cell disease and others haematological disease , and has had the pleasure of participating in multiple international meeting .
Dr. Richard Kelly
Dr. Richard Kelly is a Consultant Haematologist at Leeds Teaching Hospitals NHS Trust and Honorary Senior Lecturer at the University of Leeds, UK. He is the Leeds joint lead for the English National Paroxysmal Nocturnal Haemoglobinuria (PNH) Service. He qualified with honours from the University of St. Andrews and completed his training at the University of Manchester. He was involved in setting up the English National PNH service in 2007. In 2014 Dr. Kelly received his PhD thesis on "The Pathogenesis of PNH" with an award for research excellence from the University of Leeds and he has published key papers on PNH in peer reviewed journals. Dr Kelly is a board member of the International PNH Interest Group (IPIG) with responsibility for the design and running of the planned IPIG global PNH registry. He chairs the IPIG registry stakeholder committee and sits on the IPIG registry committee. He has been the regional lead for the acute myeloid and acute lymphoblastic leukaemia (AML and ALL) service 2014-2020. He is a principal investigator for clinical trials in PNH, MDS and haemolytic anaemias. He also sats on the NCRI AML and ALL subgroups between 2014 and 2020. Dr Kelly is a Fellow of the Royal College of Pathologists and a member of the British Society for Haematology. He is also an examiner for the Royal College of Pathologists. He has published over 55 papers.
Dr. Mohamed Abuhaleeqa 🇦🇪
Dr. Mohamed Abuhaleeqa, MBBC, is a Consultant Hematologist speculated in Leukemia and bone marrow transplant.
With over 17 years of experience, Dr. Abuhaleeqa's expertise spans Hematology, Leukemia, and Bone Marrow Transplants. In addition to his role as a consultant, he pioneered, established and was the previous director of the first Hematology Fellowship program in the Abudhabi UAE and currently active hematology and medicine Faculty. He attended Medical School at the Royal College of Surgeons in Ireland and then pursued a degree in Internal Medicine at the University of British Columbia, Canada. He further completed a subspecialty degree in Leukemia and Bone Marrow Transplant AT the British Colombia Cancer Centre, Canada. He is active member of international and regional societies American Society of Hematology, American Society of Tranplant and cellular therapy, Saudi Society of blood disorders. Currently he holds a role as advisory board member in the Transplant and cellular therapy Council in DOH. He is member of NIHS (National Institue of Health services) Emirati Board for hematology. He is member of regional and international committees of hematology. He is also active member of multiple research projects in acute and chronic myeloid and lymphoid neoplasms in UAE and member of the established Acute Leukemia Registry in UAE. He as multiple publication in Myeloma, Leukemia and bone marrow transplant. His future intrest is immunotherapy and cellular therapy.
Dr. Muna Alrasheed
Consult and head of hematology unit Adan FRCPC and ABIM internal medicine in 2005 FRCPC and ABIM in hematology in 2006 Head of examinations committee of clinical hematology fellowship
Dr.Marwa AlSayed
Started work at National blood transfusion services, AlAgouza, Giza, Egypt from 2005 until 2012. Clinical pathology Resident at Ain Shams University hospitals "Al-Demerdash Hospital" from January 2006 until January 2007. Joined Kuwait central blood bank in January 2013 and worked in both donation and immunohematology departments. Became head of immunohematology department in Kuwait central blood bank since November 2015. Clinical tutor in haematological pathology and clinical haematology programs for postgraduate training programs at Kuwait Institute for Medical specialisations.
Dr. Dina Elkady
Graduated from Faculty of medicine, Assiut University, Egypt, in 2004. Achieved master's degree in clinical pathology Faculty of medicine, from Assiut University in 2009 . Achieved MD degree in Clinical pathology and oncological laboratory medicine in 2018 and worked as a Lecturer of oncological clinical pathology, South Egypt Cancer Institute. Joined KCCC in 2019 and currently specialist of hematopathology in haematology LAB.
Dr. Nouf Alkandari
Dr. Alkandari is a hematology specialist working in Ministry of heath in Kuwait city. She graduated from Kuwait University. Then, she granted her board certificate in hematology by KIMS. She is a memeber of royal college of physicians and a clinical tutor. She is an active member of different local committees.
Dr. Noura Aljuwaisri
Clinical Hematologist and Head of the Clinical Hematology Unit, Al Amiri Hospital, Kuwait. Medical degree from the Faculty of Medicine, Kuwait University. Certified by the Kuwaiti Board of Hematology, Kuwait Institute for Medical Specializations (KIMS). Clinical Tutor, Kuwait Institute for Medical Specializations (KIMS). Member of Hemophilia Committee, Ministry of Health, Kuwait
Dr. Hanan Al Wazzan
MBBH Kuwait university Master clinical hematology United kingdom Fellowship royal college of pathology Uk Current position Hematology consultant Adan hospital Affiliate to jaber hospital Chairperson of Kuwait Hematopathology board KIMs Affiliates as clinical tutor for Kuwait medical college Member of American society of hematology Member of European society of hematology
Dr. Ahmad Al Qalaf
Dr. Ahmad AlQalaf is a board-registered pharmacist in the state of Georgia, currently serving as the Clinical Pharmacy Team Leader for the Cardiology department at Jaber Al-Ahmad Hospital in Kuwait. He holds a Bachelor of Science in Health Sciences and a Doctor of Pharmacy degree from Mercer University, and he is certified in immunization delivery by the American Pharmacists Association (APhA). Dr. AlQalaf brings a comprehensive background in clinical pharmacy, shaped through diverse rotations during his doctoral training. His rotations include ambulatory care at Grady Memorial Hospital, community pharmacy at Publix, adult acute care in cardiology and critical care in the Cardiac Intensive Care Unit at Emory Saint Joseph's Hospital, as well as academic administration at Mercer University. He also gained experience in psychiatry at Georgia Regional Hospital and OBGYN surgery at Northside Hospital. In his current role, Dr. AlQalaf leads initiatives focused on optimizing patient care in cardiology, leveraging his expertise to improve clinical outcomes and support the hospital's commitment to high-quality healthcare.
Dr. Yasmine Al Qattan
Clinical Hematology Specialist, Al-Amiri Hospital Kuwait. Clinical tutor for KIMS Clinical Hematology and Internal medicine residency programs.
Dr. Hadeel Saleh
Hadeel Saleh, consultant hematology oncology hemostasis and thrombosis-pediatric at NBK children specialized children's hospital-Kuwait . Bachelor of medicine and surgery (MBBCh);faculty of medicine ,health science center, Arabian gulf university-kingdom of Bahrain . Completed Kuwaiti board in general pediatric-Kuwait . Gained fellowship in hematology -oncology -hemostasis and thrombosis McMaster university-Hamilton-Canada . President of gulf society for hemostasis and thrombosis. president of Kuwait hematology society KHA . Had journal publications and abstract and presentations mainly in bleeding disorders. Delivered multiple presentations and speeches at regional and international conferences .
Dr. Wala Awny
Graduated and received her Master degree in Clinical Pathology from Ain Shams University.
She worked as a clinical pathology specialist in Al Helal Al Ahmar hospital and Al Helal Alahmar Main Blood Banks and Cairo Alpha labs.
She also worked as an infection control officer in Nasser Institute hospital .
In Kuwait she worked as a Medical and lab hematologist in Al Jahra General Hospital then transferred to Kuwait Cancer Control Center where she is now a senior hematopathologist
Dr. Anitha Kunhikrishnan
Dr. Anitha kunhikrishnan is a clinical hematology specialist with expertise in Acute and chronic leukemias as well as Myelomas.She has been part of the Department of Hematology at Kuwait cancer centre since 2008. She completed herMD at Calicut Medical College in India and has co authored various publications in reputed medical journals
Conference Registration
Conference Registration
Registration Deadline: 12:00 pm – 15 November 2025
Collaboration
Collaboration
Sponsors
Sponsored By
Diamond Sponsors
Platinum Sponsors
Gold Sponsors
Silver Sponsors
FAQ Section
Frequently Asked Questions
Registration Details
Please be sure to use a valid private email in the registration step.
Please be sure to write valid registration information.
Purchasing registration for multiple parties is not allowed.
Attendance Regulations
Physical Attendance: Please use the confirmed ticket sent to your registered email to get your ID from the registration desk.
CME Certificate & Regulations
In order to get the CME, please be sure that all of your data is correctly admitted through the registration process.
CME credits will be awarded to the target audience upon attending the event and scanning the QR code with our representative.
The certificate will be accessible post-event and will be sent to the email address provided during registration.
Payment Method & Refund Policy
We accept Knet and all major credit cards – VISA, Mastercard, Diners, AMEX etc.
Tickets purchased cannot be refunded for any reason.